Beyfortus Reduces Infant RSV Hospitalizations by 82%, Lancet Study Shows


According to interim results from an ongoing study published in The Lancet, Beyfortus demonstrated an 82% reduction in respiratory syncytial virus (RSV) hospitalizations among infants under 6 months old, compared to infants who did not receive any RSV intervention. The study provides real-world evidence of the effectiveness of Beyfortus in preventing severe RSV disease in young infants.

RSV is a common respiratory virus that can cause severe illness in infants and young children, often leading to hospitalization. The findings from this study underscore the potential of Beyfortus to significantly reduce the burden of RSV in this vulnerable population. As the study continues, further data will provide a more comprehensive understanding of the impact of Beyfortus in real-world settings.